Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
Study results from Harvard University, Medical Department provide new insights into prostate cancer
June 25th, 2008
According to recent research from the United States, "Failure of cancer immunotherapy is essentially due to immunological tolerance to tumor-associated antigens (TAAs), as these antigens are also expressed in healthy tissues. Here, we used transgenic adenocarcinoma of mouse prostate (TRAMP) mice, which develop lethal prostate cancer due to prostate-specific expression of SV40 T antigen (Tag), to evaluate effects of prostatic transformation on oncogene TAA-specific tolerance and to test the possibility of breaking such tolerance using a modified recombinant vaccinia virus." "We showed that Tag expression in TRAMP mice is uniquely extra-thymic, and levels of prostatic Tag...
Source: Vaccine Weekly (2008-06-25)
|
